Assessment of Sedative Activity of Lonicerin: In Vivo Approach With Pharmacokinetics and Molecular Docking
Brain and Behavior · 2025
DOI: 10.1002/brb3.70524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Tanzila Akter Eity und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology and Genetic Engineering, Gopalganj Science and Technology University, Gopalganj, Bangladesh. Hauptthemen laut MEDLINE: Hypnotics and Sedatives, Sesquiterpenes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lonicerin (LON) has been identified to have different biological properties, such as anticancer, anti‐inflammatory, immunomodulatory, antibacterial, antimicrobial, and neuroprotective. This study aims to assess the sedative effect of LON in Swiss albino mice, which is yet to be discovered. Materials and Methods: Mice were treated with two different doses of LON (5 and 10 mg/kg) and 2 mg/kg of diazepam (DZP), which is the referral GABAergic medication, and the latency time and sleeping duration of animals were observed. A computational study was also conducted to evaluate the docking scores and display the binding sites of LON and receptor (GABA A α1 and β2 subunits). The study also investigated the pharmacokinetics and drug‐likeness properties of LON along with toxicological analysis by using SwissADME and Protox‐3 software, respectively.
Results
Findings revealed that the higher concentration of LON reduced the latency (9.86 ± 1.44 min) and increased the sleep duration (191.29 ± 7.43 min) compared to the lower concentration. Besides, the combination group of LON and DZP showed the lowest latency (6.17 ± 0.82 min) and highest sleeping time (219.00 ± 6.39 min). In the in silico study, LON exhibited a strong docking score (−8.1 kcal/mol) with the macromolecules, which is closer to the binding affinity of DZP (–8.3 kcal/mol), indicating that LON could show strong sedative activity by binding with the GABA A receptor. Computational toxicity analysis revealed that LON is non‐hepatotoxic, non‐neurotoxic, noncarcinogenic, noncytotoxic, non‐ecotoxic, and non‐mutagenic.
Conclusion
Therefore, LON may be effective for the treatment of insomnia in the near future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology and Genetic Engineering, Gopalganj Science and Technology University, Gopalganj, Bangladesh.
- Bioinformatics and Drug Innovation Laboratory, BioLuster Research Center Ltd., Gopalganj, Bangladesh.
- Department of Pharmacy, Gopalganj Science and Technology University, Gopalganj, Bangladesh.
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Department of Biology, Touro University, New York City, New York, USA.
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
ORCID-Profile: Tanzila Akter Eity, Md Shimul Bhuia, Raihan Chowdhury, Salehin Sheikh, Muhammad Torequl Islam
Zitieren
APA
Eity, T. A., Bhuia, M. S., Chowdhury, R., Sheikh, S., Ansari, S. A., Ahammed, N. T., Kamli, H., & Islam, M. T. (2025). Assessment of Sedative Activity of Lonicerin: In Vivo Approach With Pharmacokinetics and Molecular Docking. Brain and Behavior. https://doi.org/10.1002/brb3.70524
Vancouver
Eity TA, Bhuia MS, Chowdhury R, Sheikh S, Ansari SA, Ahammed NT, et al. Assessment of Sedative Activity of Lonicerin: In Vivo Approach With Pharmacokinetics and Molecular Docking. Brain and Behavior. 2025. doi:10.1002/brb3.70524
BibTeX
@article{Eity2025,
author = {Eity, Tanzila Akter and Bhuia, Md Shimul and Chowdhury, Raihan and Sheikh, Salehin and Ansari, Siddique Akber and Ahammed, Nowreen Tabassum and Kamli, Hossam and Islam, Muhammad Torequl},
title = {Assessment of Sedative Activity of Lonicerin: In Vivo Approach With Pharmacokinetics and Molecular Docking},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70524}
}
EUVIMED